NEWS legal form changed ByOncoscience 22. August 201717. July 2025 We are now Oncoscience GmbH. Managing directors are Dr. Dirk Reuter, Dr. Budhi Simon and Robert Ellerson. Ähnliche Beiträge
NEWS Oncoscience AG receives EU orphan drug status for the EGFR monoclonal antibody Nimotuzumab (Theraloc®) for the treatment of pancreatic cancer. ByOncoscience 22. April 200817. July 2025
NEWS YM BioSciences’ EGFr antibody receives EU orphan drug designation through Oncoscience AG, its European partner ByOncoscience 10. August 200417. July 2025
NEWS YM BioSciences partner Oncoscience AG reports update of pediatric brain cancer data ByOncoscience 30. September 200517. July 2025
NEWS The European Medicines Agency, EMEA, concludes its formal validation of the marketing authorization application for Theraloc® (Nimotuzumab) positively ByOncoscience 26. October 200717. July 2025
NEWS YM Biosciences and Oncoscience AG achieve clinical milestone ByOncoscience 10. January 200517. July 2025
